FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3123313279> ?p ?o ?g. }

• W3123313279 endingPage "43" @default.
• W3123313279 startingPage "36" @default.
• W3123313279 abstract "Background Definitive chemoradiation with consolidative immunotherapy offers the best chance for cure in patients with unresectable, locally advanced non-small cell lung cancer (NSCLC). However, treatment-related lymphopenia (TRL) may negatively impact outcomes. Methods Patients definitively treated with chemoradiation and immunotherapy from 2015 to 2019 at a single tertiary academic center were identified. Severe lymphopenia was defined as <0.5 × 109 cells/L. Progression-free survival (PFS) was calculated by Kaplan Meier methodology. Univariate and multivariate Cox Proportional Hazard modeling was used to correlate clinical variables with disease outcome. Immune-related adverse events (irAEs) were assessed according to CTCAE version 5.0 criteria. Results Seventy-eight patients were included in the final cohort. The median age was 66 years (IQR: 58−73), 55 % were males, and 88 % had a KPS of >70. At baseline, 90 % (n = 70/78) of patients had a normal ALC and one patient had severe lymphopenia. After chemoradiation, the median ALC decreased from 1.52 × 109cells/L (IQR: 1.23–1.98) to 0.72 × 109cells/L (IQR: 0.52−0.94) (p < 0.001), 22 % (n = 17/78) of patients had a normal ALC, and 23 % (n = 18/78) of patients developed severe lymphopenia. Patients who initiated consolidative immunotherapy with severe lymphopenia had worse PFS than those who did not (median 217 days [IQR: 120–434] vs. 570 days [IQR: 401-NR], p < 0.001). On multivariate modeling, severe lymphopenia at the time of immunotherapy initiation remained an independent predictor of worse PFS (HR 4.90, p < 0.001). Conclusions This is the first report to associate severe TRL with disease progression in patients with locally advanced NSCLC receiving consolidative immunotherapy. Factors associated with development of lymphopenia and strategies to mitigate lymphopenic effects should be considered." @default.
• W3123313279 created "2021-02-01" @default.
• W3123313279 creator A5007783332 @default.
• W3123313279 creator A5018401879 @default.
• W3123313279 creator A5019578689 @default.
• W3123313279 creator A5026052001 @default.
• W3123313279 creator A5046288792 @default.
• W3123313279 creator A5052066127 @default.
• W3123313279 creator A5054587880 @default.
• W3123313279 creator A5057631025 @default.
• W3123313279 creator A5059543131 @default.
• W3123313279 creator A5060537111 @default.
• W3123313279 creator A5063752111 @default.
• W3123313279 creator A5067715440 @default.
• W3123313279 creator A5075372434 @default.
• W3123313279 creator A5075885830 @default.
• W3123313279 creator A5076608488 @default.
• W3123313279 creator A5088244674 @default.
• W3123313279 creator A5077777089 @default.
• W3123313279 date "2021-04-01" @default.
• W3123313279 modified "2023-09-30" @default.
• W3123313279 title "Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy" @default.
• W3123313279 cites W1526520296 @default.
• W3123313279 cites W1757492577 @default.
• W3123313279 cites W1982906652 @default.
• W3123313279 cites W2008259119 @default.
• W3123313279 cites W2013043293 @default.
• W3123313279 cites W2025310622 @default.
• W3123313279 cites W2030290158 @default.
• W3123313279 cites W2050188791 @default.
• W3123313279 cites W2066671159 @default.
• W3123313279 cites W2080571923 @default.
• W3123313279 cites W2083190632 @default.
• W3123313279 cites W2084659308 @default.
• W3123313279 cites W2104750134 @default.
• W3123313279 cites W2110996227 @default.
• W3123313279 cites W2115922569 @default.
• W3123313279 cites W2139758621 @default.
• W3123313279 cites W2140828776 @default.
• W3123313279 cites W2141269240 @default.
• W3123313279 cites W2270932386 @default.
• W3123313279 cites W2434730538 @default.
• W3123313279 cites W2619686289 @default.
• W3123313279 cites W2749105855 @default.
• W3123313279 cites W2753065806 @default.
• W3123313279 cites W2757014128 @default.
• W3123313279 cites W2773643507 @default.
• W3123313279 cites W2788208686 @default.
• W3123313279 cites W2789677706 @default.
• W3123313279 cites W2806116757 @default.
• W3123313279 cites W2808178081 @default.
• W3123313279 cites W2889026937 @default.
• W3123313279 cites W2891915572 @default.
• W3123313279 cites W2893824814 @default.
• W3123313279 cites W2938305221 @default.
• W3123313279 cites W2943769232 @default.
• W3123313279 cites W2944989507 @default.
• W3123313279 cites W2956407134 @default.
• W3123313279 cites W2970170486 @default.
• W3123313279 cites W2996039207 @default.
• W3123313279 doi "https://doi.org/10.1016/j.lungcan.2021.01.022" @default.
• W3123313279 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33611224" @default.
• W3123313279 hasPublicationYear "2021" @default.
• W3123313279 type Work @default.
• W3123313279 sameAs 3123313279 @default.
• W3123313279 citedByCount "25" @default.
• W3123313279 countsByYear W31233132792021 @default.
• W3123313279 countsByYear W31233132792022 @default.
• W3123313279 countsByYear W31233132792023 @default.
• W3123313279 crossrefType "journal-article" @default.
• W3123313279 hasAuthorship W3123313279A5007783332 @default.
• W3123313279 hasAuthorship W3123313279A5018401879 @default.
• W3123313279 hasAuthorship W3123313279A5019578689 @default.
• W3123313279 hasAuthorship W3123313279A5026052001 @default.
• W3123313279 hasAuthorship W3123313279A5046288792 @default.
• W3123313279 hasAuthorship W3123313279A5052066127 @default.
• W3123313279 hasAuthorship W3123313279A5054587880 @default.
• W3123313279 hasAuthorship W3123313279A5057631025 @default.
• W3123313279 hasAuthorship W3123313279A5059543131 @default.
• W3123313279 hasAuthorship W3123313279A5060537111 @default.
• W3123313279 hasAuthorship W3123313279A5063752111 @default.
• W3123313279 hasAuthorship W3123313279A5067715440 @default.
• W3123313279 hasAuthorship W3123313279A5075372434 @default.
• W3123313279 hasAuthorship W3123313279A5075885830 @default.
• W3123313279 hasAuthorship W3123313279A5076608488 @default.
• W3123313279 hasAuthorship W3123313279A5077777089 @default.
• W3123313279 hasAuthorship W3123313279A5088244674 @default.
• W3123313279 hasConcept C121608353 @default.
• W3123313279 hasConcept C126322002 @default.
• W3123313279 hasConcept C143998085 @default.
• W3123313279 hasConcept C144301174 @default.
• W3123313279 hasConcept C207103383 @default.
• W3123313279 hasConcept C2776256026 @default.
• W3123313279 hasConcept C2776694085 @default.
• W3123313279 hasConcept C2777701055 @default.
• W3123313279 hasConcept C2780739268 @default.
• W3123313279 hasConcept C38180746 @default.
• W3123313279 hasConcept C44249647 @default.

• next